Digital health case studyPharmaceutical

Decoding the Pan-Omics Venture Landscape Across Europe and Asia

Client context: Global biotech

Strategic question

Where is pan-omics innovation concentrated across Europe and Asia, and which ventures warrant deeper engagement?

Decision enabled

What the client could do next

Enabled the biotech to focus partnership and licensing engagement on a defensible prioritised set.

Approach

Using HealthTech Alpha, we evaluated 264 ventures across two regional ecosystems, applied client criteria to prioritise 63, and mapped strategic partnerships in detail to surface the most engagement-ready.

Methodology

DefineClarified the strategic question, scope, decision owner and evaluation criteria.

MapIdentified relevant ventures, markets, competitors, partnerships and ecosystem signals.

AssessEvaluated maturity, traction, evidence, strategic fit and operational readiness.

DecideTranslated findings into a decision-ready shortlist, benchmark or recommendation.

Strategic interpretation

Turned an opaque, fast-moving pan-omics space into a structured, comparative map of strategic relevance.

Key results

5Countries evaluated

264Ventures evaluated against criteria

63Prioritised shortlist

Structured digital health intelligence, venture evidence, and analyst interpretation for defensible decisions.

Alpha Brief

Turn this case study into your own decision brief

Answer a few prompts and request a scoped Alpha Brief for your market, portfolio, competitive intelligence, or due diligence question.

Build an Alpha Brief

Request a scoped proposal from this case

Decoding the Pan-Omics Venture Landscape Across Europe and Asia

Where is pan-omics innovation concentrated across Europe and Asia, and which ventures warrant deeper engagement?

What the client could do next

Approach

Methodology

Strategic interpretation

Overview

Category

Stage

Total Funding

GGA Score